Drug Type Small molecule drug |
Synonyms NP-1, AmiKet |
Target |
Mechanism Monoamine reuptake inhibitor, NMDA receptor agonists(Glutamate [NMDA] receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC20H23N |
InChIKeyKRMDCWKBEZIMAB-UHFFFAOYSA-N |
CAS Registry50-48-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neurotoxicity Syndromes | Phase 3 | - | - | |
Neurotoxicity Syndromes | Phase 3 | - | - | |
Pain | Phase 3 | - | - | |
Pain | Phase 3 | - | - | |
Peripheral Nervous System Diseases | Phase 3 | - | - | |
Peripheral Nervous System Diseases | Phase 3 | - | - | |
Behavioural disorders | Phase 2 | IN | 01 Jul 2007 | |
Diabetic peripheral neuropathy | Phase 2 | IN | 01 Jul 2007 | |
Neuralgia, Postherpetic | Phase 2 | IN | 01 Jul 2007 |
Phase 2 | 360 | (Amitriptyline 4% Ketamine 2% Cream, Placebo Capsules) | rozfxxamwk(ajlfwnhmac) = amzukhxatr iexlxfwfwr (oyzwyrpybe, qfqhhmqozh - jvqszdhhrj) View more | - | 06 Jul 2011 | ||
(Gabapentin Capsules, Placebo Cream) | rozfxxamwk(ajlfwnhmac) = yzxhmekhch iexlxfwfwr (oyzwyrpybe, xpqprnvgxh - pdiyuhatmj) View more | ||||||
Phase 2 | 226 | placebo cream (Placebo Cream) | zvndynzejr(kkxcclylht) = uchdsasqus xopihalwcw (upglrdwied, yiyeusxtph - pdslmkwjeo) View more | - | 17 May 2011 | ||
(Amitriptyline 4% Ketamine 2% Cream) | zvndynzejr(kkxcclylht) = eevdgvxefk xopihalwcw (upglrdwied, gkcyrmngof - hjoahzzaar) View more |